Trial Profile
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms BEAT-meso
- 22 Apr 2024 Planned End Date changed from 31 Jan 2024 to 1 Jun 2024.
- 22 Apr 2024 Planned primary completion date changed from 31 Jan 2024 to 1 Jun 2024.
- 29 Mar 2022 Status changed from recruiting to active, no longer recruiting.